The Graduate Program for Medical Innovation (MIP) has an organizational system to collaborate and exchange research techniques with overseas research institutes through the dispatch of MIP students and junior researchers.
- University of California, San Diego (USA)
- University of Toronto (Canada)
- National Taiwan University (Taiwan)
- The FIRC Institute of Molecular Oncology (Italy)
- National Institutes of Health (USA)
- Max-Planck Institute (Germany)
- NeuroSpin (France)
Various research institutes in Japan have deep relationships with Kyoto University in undergraduate education and graduate research in the fields of medicine and pharmaceutical sciences. Therefore, based on these existing relationships, these institutes provide students with instructions for research areas that cannot be covered solely by the university’s faculty members.
Institutions (in Japan)
- RIKEN/Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe
- Tazuke Kofukai Medical Research Institute Kitano Hospital
- Bioorganic Research Institute, Suntory Foundation for Life Sciences
The active collaboration between the MIP and private companies is not limited to research but also includes personal exchanges. These companies share the latest knowledge of the research fields that the university intends to strengthen with MIP students, for example, the research and development of next-generation multi-modal drugs, and the high-level applications of information technologies.
- NTT DATA Corporation
- Deloitte Tohmatsu Consulting LLC.
- mixi, Inc.
- KBBM, Inc.
- MICIN, Inc.
- Eisai Co., Ltd.
- Daiichi Sankyo Co., Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Asahi Kasei Pharma Corporation
- Taisho Pharmaceutical Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd.
- ONO PHARMACEUTICAL CO., LTD.
- Mitsubishi Tanabe Pharma Corporation
- KYORIN Pharmaceutical Co., Ltd.
- Chordia Therapeutics, Inc.